CryoCell International Inc (CCEL)vsNovartis AG ADR (NVS)
CCEL
CryoCell International Inc
$3.42
-3.36%
HEALTHCARE · Cap: $27.55M
NVS
Novartis AG ADR
$154.05
-0.37%
HEALTHCARE · Cap: $295.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 180772% more annual revenue ($56.58B vs $31.28M). NVS leads profitability with a 23.9% profit margin vs -8.5%. CCEL appears more attractively valued with a PEG of 1.34. NVS earns a higher WallStSmart Score of 49/100 (D+).
CCEL
Hold39
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.8%
Fair Value
$5.12
Current Price
$3.42
$1.70 discount
Margin of Safety
-67.8%
Fair Value
$91.79
Current Price
$154.05
$62.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 3.6%
Earnings declined 80.5%
Distress zone — elevated risk
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.57 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 39/100), backed by strong 23.9% margins. CCEL offers better value entry with a 34.8% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?